PARSIPPANY, N.J., June 28 /PRNewswire/ — Preliminary results
of a pre-specified subgroup study analysis of patients with
diabetes and hypertension demonstrated that the investigational
triple combination therapy of olmesartan medoxomil / amlodipine /
hydrochlorothiazide (40/10/25 mg) resulted in a statistically
significant greater Least Squares (LS) mean reduction in blood
pressure from baseline at week 12 (37.9/22.0 mm Hg versus
26.4-28.0/14.7-17.6 mm Hg, P less than or equal to 0.0013) as
compared to corresponding dual combination therapy [olmesartan
medoxomil (40 mg) / amlodipine (10 mg); olmesartan medoxomil (40
mg) / hydrochlorothiazide (25 mg); or amlodipine (10 mg) and
hydrochlorothiazide (25 mg)].(1) Blood pressure is more difficult
to control among patients with hypertension and diabetes compared
to patients with hypertension alone.(2) These findings were
presented today during a poster presentation at the American
Diabetes Association (ADA) 70th Annual Scientific Sessions in Orlando, FL.
This analysis of the TRINITY study (Triple Therapy
with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in
Hypertensive Patients
Study) also demonstrated that the investigational
triple combination therapy (40/10/25 mg) enabled more patients with
hypertension and diabetes to achieve blood pressure goal of
<130/80 mm Hg at week 12 as compared to corresponding dual
combination therapies (41.1 percent in the triple combination group
versus 10.1 to 16.3 percent in the dual combination groups, P less
than or equal to 0.0002).(1) Baseline blood pressures for those
patients receiving the triple combination therapy and corresponding
dual combination therapies were 170.7/98.3 mm Hg and
170.7-173.1/97.8-99.3 mm Hg, respectively.(1)
‘/>”/>
